Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CPMV NASDAQ:CYCC NASDAQ:NEUP OTCMKTS:NVLNF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPMVMosaic ImmunoEngineering$0.50+8.3%$0.42$0.25▼$1.03$3.65M-1.18338 shs1,225 shsCYCCCyclacel Pharmaceuticals$7.95-10.6%$7.54$3.08▼$597.60$12.60M0.08692,272 shs207,026 shsNEUPNeuphoria Therapeutics$8.10$7.42$2.12▼$12.55$15.23M0.5339,864 shs36,924 shsNVLNFNovelion Therapeutics$0.70-1.2%$0.70$0.51▼$1.00$13.77M2.15261,364 shs26,900 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPMVMosaic ImmunoEngineering0.00%+2.73%+21.73%-6.78%-50.15%CYCCCyclacel Pharmaceuticals0.00%-9.45%-39.17%-73.50%-97.39%NEUPNeuphoria Therapeutics0.00%+9.02%+8.72%+64.63%+809,999,900.00%NVLNFNovelion Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPMVMosaic ImmunoEngineeringN/AN/AN/AN/AN/AN/AN/AN/ACYCCCyclacel Pharmaceuticals1.2488 of 5 stars0.04.00.00.02.92.50.0NEUPNeuphoria Therapeutics2.3029 of 5 stars3.50.00.00.03.80.00.6NVLNFNovelion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPMVMosaic ImmunoEngineering 0.00N/AN/AN/ACYCCCyclacel Pharmaceuticals 2.00HoldN/AN/ANEUPNeuphoria Therapeutics 3.00Buy$21.00159.26% UpsideNVLNFNovelion Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPMVMosaic ImmunoEngineeringN/AN/AN/AN/A($0.94) per shareN/ACYCCCyclacel Pharmaceuticals$14K900.05N/AN/A($58.87) per share-0.14NEUPNeuphoria Therapeutics$10K1,522.80N/AN/A$15.85 per share0.51NVLNFNovelion Therapeutics$130.43M0.11N/AN/A($4.69) per share-0.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPMVMosaic ImmunoEngineering-$920K-$0.12N/A∞N/AN/AN/A-1,117.89%N/ACYCCCyclacel Pharmaceuticals-$11.21M-$839.58N/A∞N/AN/A-3,648.09%-145.49%N/ANEUPNeuphoria Therapeutics-$15.49MN/A0.00N/AN/AN/AN/AN/A9/29/2025 (Estimated)NVLNFNovelion Therapeutics-$108.33MN/A0.00∞N/AN/AN/AN/AN/ALatest CPMV, NEUP, CYCC, and NVLNF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025CYCCCyclacel Pharmaceuticals-$72.00-$0.98+$71.02-$0.98$0.03 millionN/A5/20/2025Q1 2025CPMVMosaic ImmunoEngineeringN/A-$0.03N/A-$0.03N/AN/A5/20/2025Q1 2025CPMVMosaic ImmunoEngineeringN/A-$0.03N/A-$0.03N/AN/A5/20/2025Q3 2025NEUPNeuphoria Therapeutics-$0.47$6.55+$7.02$6.55N/A$15.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPMVMosaic ImmunoEngineeringN/AN/AN/AN/AN/ACYCCCyclacel Pharmaceuticals$0.151.89%N/AN/A N/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPMVMosaic ImmunoEngineeringN/A0.020.02CYCCCyclacel PharmaceuticalsN/A5.605.60NEUPNeuphoria TherapeuticsN/A11.0111.01NVLNFNovelion TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPMVMosaic ImmunoEngineeringN/ACYCCCyclacel Pharmaceuticals23.58%NEUPNeuphoria Therapeutics15.90%NVLNFNovelion Therapeutics48.64%Insider OwnershipCompanyInsider OwnershipCPMVMosaic ImmunoEngineering80.99%CYCCCyclacel Pharmaceuticals51.20%NEUPNeuphoria Therapeutics0.69%NVLNFNovelion Therapeutics3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPMVMosaic ImmunoEngineering37.24 million1.38 millionNot OptionableCYCCCyclacel Pharmaceuticals141.59 million773,000OptionableNEUPNeuphoria TherapeuticsN/A1.88 million1.87 millionN/ANVLNFNovelion Therapeutics10919.62 millionN/ANot OptionableCPMV, NEUP, CYCC, and NVLNF HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPMV, NEUP, CYCC, and NVLNF Company DescriptionsMosaic ImmunoEngineering OTCMKTS:CPMV$0.50 +0.04 (+8.26%) As of 08/15/2025 03:45 PM EasternMosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.Cyclacel Pharmaceuticals NASDAQ:CYCC$7.95 -0.94 (-10.57%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$8.02 +0.07 (+0.88%) As of 04:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Neuphoria Therapeutics NASDAQ:NEUP$8.10 0.00 (0.00%) As of 08/15/2025 04:00 PM EasternNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.Novelion Therapeutics OTCMKTS:NVLNF$0.70 -0.01 (-1.20%) As of 01/16/2020Novelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Is Reddit Stock Too Hot, or Just Right? Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access